Clinical Trial: Tangelo
The Tangleo clinical trial, sponsored by Hoffman La Roche is now open. This is a study of the safety and tolerability of RO7248824 in children with Angelman syndrome. Participant Requirements
Below is a preliminary list of inclusion criteria:
Inclusion Criteria
- Diagnosis of Angelman syndrome
- Between 1 and 12 years old
- Stable medical status for 4 weeks prior to screening visit
- Ability to tolerate blood draws
- Able to undergo LP and IT injection, under sedation or anesthesia 3 times during an 8-week period
See the full list of Eligibility Criteria on the clinical trials website.
Locations & Contacts
Currently, the study is taking place in multiple locations world-wide.
UCLA Neuropsychiatric Institute
Los Angeles, CA
(323) 361-2471
Rady Children’s Hospital – San Diego
San Diego, CA
Lynne Bird, MD – lbird@rchsd.org
Rush University Medical Center
Chicago, IL
Kathryn Kudlacz – kathryn_l_kudlacz@rush.edu
University of North Carolina
Carrboro, NC
Hannah Riehl – hannah.riehl@cidd.unc.edu
Baylor College of Medicine/ Texas Children’s Hospital
Houston, TX
Beverly Feldman – bfeldman@bcm.edu
Ospedale Pediatrico Bambino Gesù; Dip. Neuroscienze e Neuroriabilitazione
Roma, Lazio, Italy
Erasmus MC / location Sophia Kinderziekenhuis
Rotterdam, Netherlands
Corporacio Sanitaria Parc Tauli
Sabadell, Barcelona, Spain
Hospital Universitario Virgen del Rocío
Sevilla, Spain
Hospital Sant Joan De Deu
Esplugues De Llobregas, Barcelona, Spain
More Information and Screening Enrollment
Find more information on the Roche website.
More details on clinicaltrials.gov
Questions about this study and enrollment interest can be directed to:
888-662-6728 (U.S. and Canada) or global-roche-genentech-trials@gene.com
Reference Study ID Number: BP41674
The Angelman Syndrome Foundation does not endorse any clinical trial or study, but provides information to the AS community for its own consideration.